Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer

Background: It is unclear whether changes in serum tumor marker expression post-treatment are of prognostic value. We investigated the associations between changes in serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) after first-line treatment and overall survival (OS) in non-small cell lung cancer (NSCLC).

Methods: Advanced NSCLC patients (April 2010 to December 2015) with elevated serum CEA or CYFRA 21-1 were included. The associations between tumor marker changes after treatment initiation and OS were analyzed.

Results: Ninety-six and 55 patients were CEA- and CYFRA 21-1-positive, respectively. The serum CEA response at 4 months and CYFRA 21-1 responses at 1 and 4 months were significantly associated with OS in the univariate analyses (P=0.025, P=0.016 and P<0.001, respectively). Moreover, in the multivariate analyses, serum CYFRA 21-1 response at 4 months was significantly associated with improved OS (P=0.038).

Conclusions: In NSCLC patients, serum CEA and CYFRA 21-1 responses after treatment initiation may predict longer OS.

Media Type:

Electronic Article

Year of Publication:

2019

Contained In:

Translational lung cancer research - Vol. 8, No. 3 (2019), p. 227-234

Language:

English

Contributors:

Yoshimura, Akihiro
Uchino, Junji
Hasegawa, Koichi
Tsuji, Taisuke
Shiotsu, Shinsuke
Yuba, Tatsuya
Takumi, Chieko
Yamada, Tadaaki
Takayama, Koichi
Hiraoka, Noriya

Links:

Volltext

Keywords:

Carcinoembryonic antigen (CEA)
Chemotherapy
Cytokeratin 19 fragment
Journal Article
Non-small cell lung cancer (NSCLC)
Prognostic factor

Notes:

Date Revised 28.09.2020

published: Print

Citation Status PubMed-not-MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.21037/tlcr.2019.06.08

PMID:

31367536

PPN (Catalogue-ID):

NLM300433956